Denmark’s national authorities have confirmed to The Center for Biosimilars® that AbbVie's Humira did not offer the lowest price for adalimumab in either of 2 national tenders.
Stakeholders across the biosimilars landscape have been eagerly awaiting the results of European national tenders for adalimumab following the October launches of multiple biosimilars. Now, Denmark has revealed that AbbVie, maker of the reference adalimumab, Humira, did not win the highest ranking in either 2 national tenders for adalimumab.
Amgros, the Danish national tendering authority that serves as a procurement services for the 5 regional authorities of Denmark, said in an email to The Center for Biosimilars® that it has conducted 2 tenders for adalimumab. The first tender covers a brief period (January 2019 to March 2019), while the second covers a more extensive period (April 2019 to December 2019, with options to extend the arrangement).
According to a spokesperson for Amgros, “In both tenders for adalimumab 40 mg, we have entered into agreements with 5 companies—the agreements are ranked according to price. In both tenders, we have signed an agreement with AbbVie for Humira—but Humira does not have the lowest price (ie, is not the winner with the highest ranking).”
Amgros added that the full rankings of companies—and the prices of each of the adalimumab products—will be disclosed publicly on January 1 and April 1, the respective dates on which the 2 tenders’ signed agreements become effective.
Denmark’s tender is likely to have ripple effects throughout other nations in Europe; many European countries use reference pricing systems that rely on pricing in countries like Denmark as a benchmark. For example, in Iceland, the price of a biosimilar cannot be higher than the lowest wholesale price among Denmark, Norway, Sweden, and Finland. Likewise, in Bulgaria, a biosimilar’s price cannot exceed the price in 17 nations, including Denmark.
Denmark is so often relied upon for reference pricing because of its strong track record in reducing cost burdens on its healthcare system through the use of biosimilars. Furthermore, its coordinated approach to biosimilar adoption has allowed for smooth transitions to these lower-cost agents.
During the fifth DIA Biosimilars Conference, held October 22 to 23, 2018, in London, United Kingdom, Amgros’ Dorthe Bartels, MSc, explained that, when biosimilar infliximab became available in 2015, educational efforts and clinical guidelines including biosimilar options were established prior to CT-P13’s launch. As a result of increased awareness of and comfort with biosimilars among stakeholders, Denmark was able to achieve nearly 100% uptake of biosimilar infliximab within 3 months of its availability.
Bartles also explained that Amgros is well prepared to bring biosimilar adalimumab to its hospitals, having learned valuable lessons from its roll-outs of biosimilar infliximab and filgrastim in its system.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.